The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase
worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease …

Inflammatory bowel disease is characterized by significant interindividual heterogeneity.
With a wider selection of pharmacologic and nonpharmacologic interventions available and …

Background: Up to a third of inflammatory bowel disease) patients show primary
nonresponse to antitumor necrosis factor (anti-TNF) biological therapy, and of those who …

Infliximab and adalimumab are monoclonal antibodies against tumor necrosis factor (anti-
TNF) used to manage inflammatory bowel disease (IBD). Therapeutic Drug Monitoring …

Background There is a growing body of primary evidence on the cost-effectiveness of
applying therapeutic drug monitoring (TDM) for inflammatory bowel disease (IBD) …

Background: Therapeutic drug monitoring (TDM) is a decision-making tool for optimizing the
use of certain therapies. In this article, the authors review the role of proactive TDM of …

Highlights•Biologics are effective, but expensive, therapies for inflammatory bowel
disease.•Therapeutic drug monitoring reduces biologic costs through better drug …

Monoclonal antibodies (MAbs) have revolutionized the treatment of many chronic
inflammatory diseases, including inflammatory bowel disease (IBD). IBD is a term that …

Background: Substantial inter-and intra-individual variability of Infliximab (IFX)
pharmacokinetics necessitates tailored dosing approaches. Here, we evaluated the …

Infliximab (IFX) concentrations are a predictive factor (PF) of pharmacokinetic (PK) origin in
the treatment of Crohn's disease (CD). We evaluated Clearance, another PF of PK origin …